Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by retiredcfon Dec 29, 2023 9:34am

355 Views

Post# 35803783

Keystone Financial

KeyStone’s Latest Small-Cap Growth Stock Recommendation:

Cipher Pharmaceuticals (CPH:TSX)
Recommended: August 28, 2023, at $3.89
Today's Price: $5.70
Gain: 46.5%

Cipher (CPH:TSX) is a unique specialty pharmaceutical company that is profitable, growing organically & via acquisitions, with a strong cash rich (35% of its value in cash & no debt) balance sheet. The stock just reported record financial results last week and the stock has jumped to new highs. Cipher is a recent excellent example of how research can produce strong gains for clients.